Anthem Biosciences Limited, an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO), announced its consolidated unaudited financial results for the quarter ended June 30, 2025.

For Q1 FY26, consolidated revenue from operations stood at Rs. 540 .2 crore, representing a 59.5 per cent year-on-year growth and an 11.8 per cent increase from the previous quarter.

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase, while the Specialty Ingredients business delivered Rs. 87.5 crore, reflecting a 19.7 per cent YoY rise. Including other income of Rs. 22.8 crore, total revenues for the quarter reached Rs. 563 crore, up 57.3 per cent year-on-year.

EBITDA for the quarter was Rs. 214.3 crore, up 52.7 per cent from the same period last year, with margins at 38 per cent. Profit before tax came in at Rs.186.2 crore, a 57.9 per cent increase YoY, while Profit After Tax rose 64.8 per cent to Rs.135.8 crore, delivering a PAT margin of 24 per cent. The company reported a net cash position of Rs.784.8 crore as of June 30, 2025.

Commenting on the results, Ajay Bhardwaj, Chairman, Managing Director, and CEO of Anthem Biosciences Limited, said "We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. The significant year-on-year growth in Q1 reflects the ramp-up in our CRDMO revenue stream that began in Q2 FY25. Our performance across both the CRDMO and Specialty Ingredients businesses has been driven by a combination of a dedicated team, strategic focus, operational excellence, and long-standing client partnerships."